Chime Biologics Announced the Expansion of GMP Manufacturing Capacity with Construction of a Second GMP Facility (GMP-2)

  • The GMP-2 facility will include expanded drug substance capacity with 8 x 2000L GMP mammalian cell culture production lines
  • Lyophilization and PFS fill & finish drug product lines will add to Chime’s integrated manufacturing capability
  • The expanded capacity and capability will increase flexibility to scale between early-stage and late-stage production

[August 4, 2021 GMT +8] – Chime Biologics (‘Chime’), a world-class contract development and manufacturing organization (CDMO), announced the construction of GMP-2 facility.

The GMP-2 expansion project will provide increased capacity of 8 x 2000L GMP mammalian cell culture together with Lyophilization and PFS fill & finish lines to fully support Chime’s GMP-1 and GMP-2 production lines. The GMP-2 facility is expected to be ready for GMP manufacturing in end of 2022, then Chime’s total production capacity will be around 28,000 liters. With this expansion, the MSAT and protein science labs are also upgraded and expanded, to better support process development, characterization and qualification, to deliver clinical and commercial projects compliant with global standards on time and within budget.

Andrew Ng, director of board of Chime Biologics, officials of Wuhan East Lake High-Tech Development zone and Hubei provincial FDA strategic clients and partners joined the groundbreaking and gave speeches.

Dr. John Zeng, CEO of Chime Biologics, said, “I’m very pleased Chime’s GMP-2 expansion project has started today. The completion of the GMP-2 project will enhance Chime’s capacity to deliver clinical and commercial drug substance and product for global supply. We look forward to the completion of the GMP-2 project and will continue to provide customers with high-quality and comprehensive CDMO services.

With the operation of the GMP-1 facility since 2013, Chime has 100% successfully delivered more than 30 projects, supplying to more than 20 countries. Most of the projects scale to 2000L GMP cell culture for production with matching scale downstream processing. Recent projects include a validated NDA submission to NMPA and anticipate pre-approval inspection later this year and a multi-country commercial supply project for a potential COVID-19 therapeutic antibody.

About Chime Biologics

Chime Biologics is a global leading CDMO that has introduced the first modular biopharmaceutical plant KUBio in the world to empower its partners’ success in biologics in the whole process from cell line development to commercial manufacturing. Relying on cell line development and advanced technology development from our Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan plant, Chime Biologics is providing a one-stop CMC solution for biopharmaceutical customers around the world. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling its commitment to human health. For more information, please visit www.chimebiologics.com.